Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

ClinicalTrials.gov ID: NCT01316237

Public ClinicalTrials.gov record NCT01316237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection.

Study identification

NCT ID
NCT01316237
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
90 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Sep 30, 2011
Completion
Dec 31, 2011
Last update posted
Mar 25, 2012

2011 – 2012

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
Advanced Clinical Research Institute Anaheim California 92801
Axis Clinical Trials Los Angeles California 90057
Avail Clinical Research, LLC DeLand Florida 32720
University of Florida - Gainesville Gainesville Florida 32608
Orlando Immunology Center Orlando Florida 32803
Orlando Clinical Research Center Orlando Florida 32809
Saint Louis University St Louis Missouri 63104
CRI Worldwide Philadelphia Pennsylvania 19139
St. Luke Episcopal Hospital Houston Texas 77030
Alamo Medical Research San Antonio Texas 78215
Lifetree Clinical Research, LC Salt Lake City Utah 84106
Charles River Clinical Services Northwest Tacoma Washington 98418

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01316237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 25, 2012 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01316237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →